Sign in

Acute myeloid leukaemia: trials that stopped early

Trials on Acute myeloid leukaemia that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

167 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.

  1. Terminated

    Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

    Reason given in the registry

    “FDA Clinical Hold”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Nov 2026.

    Ended
    Oct 2026
    Phase
    Phase 1
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT02530034
  2. Withdrawn

    Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

    Reason given in the registry

    “Budgetary constraints”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Oct 2026.

    Phase
    Phase 1
    Run by
    Virginia Commonwealth University
    Registry record
    NCT07130695
  3. Terminated

    Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

    Reason given in the registry

    “No longer have funding support to complete the pharmacogenetics component.”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Oct 2026.

    Ended
    Mar 2025
    Phase
    Phase 2
    Run by
    Medical College of Wisconsin
    Registry record
    NCT03150004
  4. Suspended

    Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

    Reason given in the registry

    “Accrual goal Met”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Oct 2026.

    Phase
    Phase 1
    Run by
    City of Hope Medical Center
    Registry record
    NCT03969446
  5. Suspended

    Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

    Reason given in the registry

    “resources”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Oct 2026.

    Phase
    Phase 1
    Run by
    City of Hope Medical Center
    Registry record
    NCT06454409
  6. Suspended

    8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Reason given in the registry

    “Safety Issues, status is being updated per PI due to safety issues. Study is now Temporarily Closed to Accrual.”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Oct 2026.

    Phase
    Phase 1
    Run by
    City of Hope Medical Center
    Registry record
    NCT05263284
  7. Suspended

    Pyronaridine in Acute Myeloid Leukemia (AML)

    Reason given in the registry

    “Change of protocol”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Oct 2026.

    Phase
    Phase 2
    Run by
    Armaceutica, Inc.
    Registry record
    NCT05291390
  8. Terminated

    A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

    Reason given in the registry

    “Early discontinuation based on strategic sponsor decision not driven by any safety concerns”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Oct 2026.

    Ended
    Aug 2025
    Phase
    Phase 1/2
    Run by
    Sanofi
    Registry record
    NCT06508489
  9. Terminated

    AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

    Reason given in the registry

    “\<75% participation”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2026.

    Ended
    Oct 2026
    Phase
    Phase 2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT04062266
  10. Suspended

    Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

    Reason given in the registry

    “Timeline Adjustment”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 Oct 2026.

    Phase
    Phase 1
    Run by
    City of Hope Medical Center
    Registry record
    NCT06195891
  11. Terminated

    Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia

    Reason given in the registry

    “Inclusion is proceeding too slowly”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Oct 2026.

    Ended
    Jul 2024
    Run by
    Centre Hospitalier Universitaire de Saint Etienne
    Registry record
    NCT03439371
  12. Terminated

    Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Reason given in the registry

    “Inability to meet protocol objectives”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Oct 2026.

    Ended
    Aug 2026
    Phase
    Phase 1
    Run by
    Bristol-Myers Squibb
    Registry record
    NCT06419634
  13. Suspended

    Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE

    Reason given in the registry

    “Planned interim analyse”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Oct 2026.

    Phase
    Phase 2
    Run by
    Institut Paoli-Calmettes
    Registry record
    NCT06055621
  14. Suspended

    Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

    Reason given in the registry

    “Trial being transferred to new lead site”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Sept 2026.

    Phase
    Phase 1
    Run by
    Huda Salman
    Registry record
    NCT06197672
  15. Terminated

    Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

    Reason given in the registry

    “poor accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Sept 2026.

    Ended
    Jan 2025
    Phase
    Early phase 1
    Run by
    Base Therapeutics (Shanghai) Co., Ltd.
    Registry record
    NCT06541405
  16. Terminated

    Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

    Reason given in the registry

    “poor accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Sept 2026.

    Ended
    Jun 2025
    Phase
    Early phase 1
    Run by
    Base Therapeutics (Shanghai) Co., Ltd.
    Registry record
    NCT06541444
  17. Terminated

    A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada

    Reason given in the registry

    “Strategic Considerations”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Sept 2026.

    Ended
    Aug 2026
    Run by
    AbbVie
    Registry record
    NCT05424562
  18. Terminated

    A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

    Reason given in the registry

    “Sponsor decision (No safety concern)”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Sept 2026.

    Ended
    Nov 2025
    Phase
    Phase 1/2
    Run by
    Takeda
    Registry record
    NCT05886491
  19. Terminated

    Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

    Reason given in the registry

    “Sponsor prioritization of other development portfolio”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Sept 2026.

    Ended
    Sept 2026
    Phase
    Phase 1
    Run by
    SystImmune Inc.
    Registry record
    NCT06714591
  20. Terminated

    RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

    Reason given in the registry

    “RPD2 has been identified”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Sept 2026.

    Ended
    May 2024
    Phase
    Phase 1
    Run by
    Ryvu Therapeutics SA
    Registry record
    NCT04021368
  21. Terminated

    Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

    Reason given in the registry

    “Sponsor decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Sept 2026.

    Ended
    Sept 2025
    Phase
    Phase 2
    Run by
    Ryvu Therapeutics SA
    Registry record
    NCT06268574
  22. Terminated

    BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

    Reason given in the registry

    “Company Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Sept 2026.

    Ended
    Sept 2026
    Phase
    Phase 1/2
    Run by
    BlueSphere Bio, Inc
    Registry record
    NCT06704152
  23. Withdrawn

    Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

    Reason given in the registry

    “Company Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Sept 2026.

    Ended
    Sept 2026
    Phase
    Phase 1
    Run by
    BlueSphere Bio, Inc
    Registry record
    NCT07566585
  24. Suspended

    ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

    Reason given in the registry

    “insufficient funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Sept 2026.

    Phase
    Phase 2
    Run by
    Leland Metheny
    Registry record
    NCT06680661
  25. Withdrawn

    Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML

    Reason given in the registry

    “Strategic adjustment.”

    Quoted unchanged from ClinicalTrials.gov; record updated 26 Aug 2026.

    Ended
    Mar 2026
    Phase
    Early phase 1
    Run by
    First Affiliated Hospital of Guangxi Medical University
    Registry record
    NCT07338357
  26. Suspended

    Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

    Reason given in the registry

    “Other - Pending amendment for study expansion.”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Aug 2026.

    Phase
    Phase 1
    Run by
    National Cancer Institute (NCI)
    Registry record
    NCT06514261
  27. Suspended

    Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

    Reason given in the registry

    “Drug Supply Issues”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Aug 2026.

    Phase
    Phase 1
    Run by
    National Cancer Institute (NCI)
    Registry record
    NCT06802523
  28. Terminated

    A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia

    Reason given in the registry

    “Interim Analysis per Protocol”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Aug 2026.

    Ended
    Aug 2025
    Phase
    Phase 2
    Run by
    University of Michigan Rogel Cancer Center
    Registry record
    NCT05780879
  29. Terminated

    ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

    Reason given in the registry

    “\<75% participants”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Aug 2026.

    Ended
    Aug 2026
    Phase
    Phase 1/2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT02392572
  30. Suspended

    DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial

    Reason given in the registry

    “Recruitment on hold with plans to open to accrual again soon.”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Aug 2026.

    Phase
    Phase 1
    Run by
    Fred Hutchinson Cancer Center
    Registry record
    NCT06492707

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.